ArticleBMC cancer2018

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).

Motoko Tachihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.